M S Patnaik

List of Publications by Citations

464	6,752	42	70
papers	citations	h-index	g-index
488	8,586	4.4	6.31
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
464	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood*, **2009**, 113, 5727-36	2.2	399
463	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. *Blood*, **2019**, 133, 697-709	2.2	253
462	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. *New England Journal of Medicine*, **2015**, 373, 908-19	59.2	219
461	Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. *Leukemia*, **2009**, 23, 1343-5	10.7	219
460	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. *Leukemia*, **2014**, 28, 2206-12	10.7	186
459	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood*, **2012**, 119, 569-72	2.2	164
458	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. *Leukemia*, **2013**, 27, 1504-10	10.7	151
457	Myelodysplastic syndromes: Contemporary review and how we treat. *American Journal of Hematology*, **2016**, 91, 76-89	7.1	119
456	Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. *American Journal of Hematology*, **2013**, 88, 201-6	7.1	112
455	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. *Leukemia*, **2012**, 26, 101-5	10.7	112
454	FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. *Leukemia Research*, **2006**, 30, 965-70	2.7	110
453	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. *American Journal of Hematology*, **2014**, 89, 1111-5	7.1	104
452	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. *Blood Cancer Journal*, **2015**, 5, e333	7	89
451	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2016**, 6, e385	7	83
450	The complete evaluation of erythrocytosis: congenital and acquired. *Leukemia*, **2009**, 23, 834-44	10.7	83
449	Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. *Blood*, **2016**, 127, 1449-58	2.2	81
448	Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2016**, 6, e393	7	80

447	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. *Leukemia*, **2013**, 27, 2100-2	10.7	75
446	Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. *British Journal of Haematology*, **2014**, 165, 273-86	4.5	74
445	Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. *Leukemia*, **2011**, 25, 266-70	10.7	73
444	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. *American Journal of Hematology*, **2018**, 93, 824-840	7.1	73
443	WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. *Leukemia*, **2010**, 24, 1283-9	10.7	72
442	The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 605-616	4.7	71
441	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. *Leukemia*, **2018**, 32, 1200-1210	10.7	68
440	Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. *Blood*, **2012**, 119, 5674-7	2.2	59
439	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. *Haematologica*, **2019**, 104, 1935-1949	6.6	58
438	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. *American Journal of Hematology*, **2016**, 91, 492-8	7.1	55
437	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. *Blood Advances*, **2018**, 2, 370-380	7.8	55
436	Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. *American Journal of Hematology*, **2020**, 95, 97-115	7.1	54
435	The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. *Cancer Journal (Sudbury, Mass)*, **2016**, 22, 40-50	2.2	54
434	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Mayo Clinic Proceedings*, **2019**, 94, 599-610	6.4	50
433	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. *American Journal of Hematology*, **2017**, 92, 1311-1317	7.1	50
432	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. *EBioMedicine*, **2018**, 31, 174-181	8.8	49
431	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. *Blood Cancer Journal*, **2017**, 7, e584	7	49
430	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. *American Journal of Hematology*, **2017**, 92, 56-61	7.1	48

429	The importance of FLT3 mutational analysis in acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 2273-2286	1.9	48
428	Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. *Clinical Epigenetics*, **2016**, 8, 68	7.7	47
427	Radius: A Phase 2 Randomized Trial Investigating Standard of Care Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML. *Blood*, **2018**, 132, 662-662	2.2	47
426	Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. *American Journal of Hematology*, **2016**, 91, 631-42	7.1	47
425	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. *Haematologica*, **2020**, 105, 348-357	6.6	46
424	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. *American Journal of Hematology*, **2015**, 90, 411-6	7.1	45
423	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. *Blood Advances*, **2019**, 3, 508-518	7.8	43
422	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 542-548	7.1	41
421	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematology,the*, **2020**, 7, e601-e612	14.6	41
420	Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside. *Mayo Clinic Proceedings* , **2018**, 93, 904-916	6.4	41
419	Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. *Blood Cancer Journal*, **2017**, 7, e592	7	40
418	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. *Oncotarget*, **2017**, 8, 27145-27154	3.3	40
417	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. *Leukemia*, **2020**, 34, 1407-1421	10.7	40
416	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Advances*, **2018**, 2, 2964-2972	7.8	40
415	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*, **2017**, 92, 297-310	7.1	39
414	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. *Mayo Clinic Proceedings*, **2017**, 92, 1617-1624	6.4	39
413	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. *Blood Research*, **2014**, 49, 100-6	1.4	38
412	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. *Leukemia*, **2019**, 33, 2466-2480	10.7	37

411	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. *American Journal of Hematology*, **2018**, 93, 65-73	7.1	37
410	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1488-1493	1.9	35
409	Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. *Cancer Medicine*, **2015**, 4, 490-9	4.8	35
408	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. *American Journal of Hematology*, **2018**, 93, 691-697	7.1	34
407	Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. *European Journal of Haematology*, **2010**, 84, 105-8	3.8	34
406	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. *Blood Cancer Journal*, **2016**, 6, e472	7	32
405	Monocytosis in polycythemia vera: Clinical and molecular correlates. *American Journal of Hematology*, **2017**, 92, 640-645	7.1	31
404	Refractory anemia with ring sideroblasts and RARS with thrombocytosis. *American Journal of Hematology*, **2015**, 90, 549-59	7.1	31
403	Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. *American Journal of Hematology*, **2010**, 85, 238-42	7.1	31
402	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. *Blood Cancer Journal*, **2018**, 8, 12	7	30
401	Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. *Transplant Infectious Disease*, **2016**, 18, 913-920	2.7	30
400	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. *American Journal of Hematology*, **2013**, 88, 690-3	7.1	29
399	A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). *Frontiers in Immunology*, **2019**, 10, 777	8.4	28
398	A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. *Blood*, **2016**, 128, 1913-1917	2.2	28
397	Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. *Blood*, **2020**, 136, 909-913	2.2	28
396	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. *American Journal of Hematology*, **2020**, 95, 1511-1521	7.1	28
395	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *American Journal of Hematology*, **2019**, 94, 767-779	7.1	27
394	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. *Bone Marrow Transplantation*, **2019**, 54, 204-211	4.4	27

393	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1478-1484	4.7	26
392	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. *American Journal of Hematology*, **2018**, 93, 649-654	7.1	26
391	Genotype-Phenotype Correlation of Hereditary Erythrocytosis Mutations, a single center experience. *American Journal of Hematology*, **2018**, 93, 1029	7.1	26
390	Aberrant expression of CD123 (interleukin-3 receptor-□) on neoplastic mast cells. *Leukemia*, **2015**, 29, 1605-8	10.7	25
389	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. *Blood Cancer Journal*, **2016**, 6, e405	7	24
388	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. *Journal of Clinical Oncology*, **2021**, 39, 48-56	2.2	24
387	ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. *Blood Cancer Journal*, **2015**, 5, e315	7	23
386	Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: a retrospective study. *Thrombosis Research*, **2015**, 135, 109-13	8.2	23
385	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. *British Journal of Haematology*, **2018**, 183, 835-838	4.5	23
384	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". *American Journal of Hematology*, **2019**, 94, 475-488	7.1	23
383	Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. *Bone Marrow Transplantation*, **2021**, 56, 1180-1189	4.4	22
382	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. *Blood Cancer Journal*, **2015**, 5, e270	7	21
381	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. *Blood*, **2020**, 136, 1477-1486	2.2	21
380	Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. *European Journal of Haematology*, **2010**, 84, 518-24	3.8	21
379	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. *American Journal of Hematology*, **2017**, 92, E614-E618	7.1	20
378	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. *Leukemia*, **2018**, 32, 1850-1856	10.7	19
377	Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. *Mayo Clinic Proceedings*, **2016**, 91, 259-72	6.4	19
376	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia*, **2018**, 32, 2512-2518	10.7	19

375	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 453-453	2.2	19
374	Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 2248-2248	2.2	19
373	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1431-1439	4.7	18
372	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. *Leukemia and Lymphoma*, **2017**, 58, 872-881	1.9	18
371	Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. *American Journal of Hematology*, **2011**, 86, 393-8	7.1	18
370	Mutations and karyotype predict treatment response in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, 1420-1426	7.1	18
369	Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. *American Journal of Hematology*, **2016**, 91, E12-4	7.1	17
368	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. *American Journal of Hematology*, **2018**, 93, 1461-1466	7.1	17
367	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. *Blood*, **2019**, 134, 558-558	2.2	17
366	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. *Blood*, **2016**, 128, 100-100	2.2	17
365	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. *Blood Advances*, **2020**, 4, 3677-3687	7.8	17
364	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. *American Journal of Hematology*, **2021**, 96, 781-789	7.1	17
363	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation. *American Journal of Hematology*, **2016**, 91, E10-1	7.1	17
362	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. *Leukemia*, **2020**, 34, 656-661	10.7	17
361	Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. *Laboratory Investigation*, **2017**,	5.9	16
360	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. *Blood Cancer Journal*, **2016**, 6, e414	7	16
359	Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 579-83	4.7	16
358	Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. *Blood*, **2014**, 124, 5577-5577	2.2	16

357	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. *Leukemia*, **2016**, 30, 2273-2275	10.7	16
356	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 546-9	2	15
355	Clinical and laboratory characteristics in congenital ANKRD26 mutation-associated thrombocytopenia: A detailed phenotypic study of a family. *Platelets*, **2016**, 27, 712-715	3.6	15
354	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. *Blood Cancer Journal*, **2017**, 7, e550	7	14
353	Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). *American Journal of Hematology*, **2018**, 93, E27-E30	7.1	14
352	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clinic Proceedings*, **2018**, 93, 1363-1374	6.4	14
351	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. *Journal of Clinical Oncology*, **2021**, 39, 3328-3339	2.2	14
350	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. *American Journal of Clinical Pathology*, **2016**, 146, 86-94	1.9	14
349	Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation: Stem Cell Donation Behaviors. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1710-1716	4.7	14
348	Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. *European Journal of Haematology*, **2016**, 97, 313-20	3.8	14
347	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. *Blood Cancer Journal*, **2018**, 8, 82	7	14
346	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer Journal*, **2018**, 8, 18	7	13
345	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1906-1913	4.7	13
344	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. *Mayo Clinic Proceedings*, **2019**, 94, 1753-1768	6.4	13
343	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). *Blood Cancer Journal*, **2017**, 7, 658	7	13
342	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the V617F mutation. *Haematologica*, **2019**, 104, e236-e239	6.6	13
341	Clinical Correlates and Treatment Outcomes for Patients With Short Telomere Syndromes. *Mayo Clinic Proceedings*, **2018**, 93, 834-839	6.4	13
340	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. *American Journal of Hematology*, **2017**, 92, 866-871	7.1	12

339	Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. *Transplant Infectious Disease*, **2016**, 18, 216-26	2.7	12
338	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. *Transfusion*, **2016**, 56, 518-27	2.9	12
337	Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2019**, 9, 65	7	12
336	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. *Nature Communications*, **2021**, 12, 2901	17.4	12
335	WILD syndrome is GATA2 deficiency: A novel deletion in the GATA2 gene. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 1149-1152.e1	5.4	11
334	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. *Leukemia Research*, **2018**, 71, 60-62	2.7	11
333	Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature. *American Journal of Hematology*, **2015**, 90, E183-4	7.1	11
332	Molecular diagnosis of myeloproliferative neoplasms. *Expert Review of Molecular Diagnostics*, **2009**, 9, 481-92	3.8	11
331	Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. *Leukemia Research Reports*, **2016**, 5, 7-10	0.6	11
330	Association between anemia and hematological indices with mortality among cardiac intensive care unit patients. *Clinical Research in Cardiology*, **2020**, 109, 616-627	6.1	11
329	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. *Blood Cancer Journal*, **2021**, 11, 49	7	11
328	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. *Leukemia and Lymphoma*, **2017**, 58, 2588-2597	1.9	10
327	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. *Mayo Clinic Proceedings*, **2015**, 90, 1623-38	6.4	10
326	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. *Blood Advances*, **2020**, 4, 5425-5430	7.8	10
325	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. *Leukemia*, **2020**, 34, 2519-2524	10.7	10
324	CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. *Leukemia*, **2014**, 28, 1370-1	10.7	10
323	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. *Blood Cancer Journal*, **2013**, 3, e122	7	10
322	Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. *European Journal of Haematology*, **2017**, 99, 275-282	3.8	10

321	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 699-704	2	10
320	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. *Blood*, **2013**, 122, 662-662	2.2	10
319	Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. *British Journal of Haematology*, **2019**, 187, e51-e54	4.5	9
318	Hereditary Predisposition to Hematopoietic Neoplasms: When Bloodline Matters for Blood Cancers. *Mayo Clinic Proceedings*, **2020**, 95, 1482-1498	6.4	9
317	Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. *Best Practice and Research in Clinical Haematology*, **2020**, 33, 101171	4.2	9
316	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. *Blood Cancer Journal*, **2018**, 8, 32	7	9
315	Acute leukemia in pregnancy: a single institution experience with 23 patients. *Leukemia and Lymphoma*, **2017**, 58, 1052-1060	1.9	9
314	Coagulation abnormalities and haemostatic surgical outcomes in 142 patients with Noonan syndrome. *Haemophilia*, **2017**, 23, e237-e240	3.3	9
313	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2018**, 132, 1821-1821	2.2	9
312	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. *Blood*, **2020**, 136, 19-21	2.2	9
311	Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 450-459	3.1	9
310	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. *Blood Cancer Journal*, **2019**, 9, 11	7	8
309	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. *Haematologica*, **2020**, 105, e84-e86	6.6	8
308	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. *Leukemia and Lymphoma*, **2018**, 59, 2737-2739	1.9	8
307	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. *Mayo Clinic Proceedings*, **2019**, 94, 1467-1474	6.4	8
306	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. *Blood*, **2018**, 132, 463-463	2.2	8
305	Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. *Current Oncology Reports*, **2019**, 21, 101	6.3	8
304	Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". *American Journal of Hematology*, **2021**, 96, 379-394	7.1	8

303	Midostaurin for the treatment of acute myeloid leukemia. *Future Oncology*, **2017**, 13, 1853-1871	3.6	7
302	Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia. *Leukemia and Lymphoma*, **2017**, 58, 1963-1967	1.9	7
301	Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. *Leukemia Research*, **2015**, 39, 1207-1207	2.7	7
300	A population-based study of chronic neutrophilic leukemia in the United States. *Blood Cancer Journal*, **2020**, 10, 68	7	7
299	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. *American Journal of Hematology*, **2020**, 95, E203-E208	7.1	7
298	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. *American Journal of Hematology*, **2018**, 93, E146-E148	7.1	7
297	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. *American Journal of Hematology*, **2018**, 93, 1347-1357	7.1	7
296	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2020**, 10, 121	7	7
295	Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 460-464	3.1	7
294	Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. *Mayo Clinic Proceedings*, **2021**, 96, 2653-2659	6.4	7
293	Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms. *Rheumatic Disease Clinics of North America*, **2020**, 46, 429-444	2.4	6
292	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. *Blood Cancer Journal*, **2020**, 10, 36	7	6
291	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. *Leukemia and Lymphoma*, **2020**, 61, 1592-1600	1.9	6
290	The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. *Journal of Biological Chemistry*, **2020**, 295, 2698-2712	5.4	6
289	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. *American Journal of Clinical Pathology*, **2020**, 153, 656-663	1.9	6
288	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. *American Journal of Hematology*, **2020**, 95, E114-E117	7.1	6
287	Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e39-41	2	6
286	Safety of pegfilgrastim (neulasta) in patients with sickle cell trait/anemia. *Case Reports in Hematology*, **2013**, 2013, 146938	0.7	6

285	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. *Blood*, **2020**, 136, 39-40	2.2	6
284	Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. *Advances in Cell and Gene Therapy*, **2019**, 2, e48	1.2	6
283	Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia. *Leukemia and Lymphoma*, **2019**, 60, 1337-1339	1.9	6
282	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. *Modern Pathology*, **2020**, 33, 334-343	9.8	6
281	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. *Leukemia*, **2021**, 35, 644-649	10.7	6
280	Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. *Human Immunology*, **2018**, 79, 532-536	2.3	5
279	FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. *Leukemia and Lymphoma*, **2018**, 59, 1520-1522	1.9	5
278	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. *Leukemia and Lymphoma*, **2018**, 59, 2998-3001	1.9	5
277	Etiologies of Extreme Thrombocytosis: A Contemporary Series. *Mayo Clinic Proceedings*, **2019**, 94, 1542-1550	6.4	5
276	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Advances*, **2020**, 4, 5716-5721	7.8	5
275	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. *Leukemia and Lymphoma*, **2019**, 60, 990-999	1.9	5
274	Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities. *Current Hematologic Malignancy Reports*, **2017**, 12, 290-299	4.4	4
273	Iron deficiency anemia associated with extracorporeal photopheresis: A retrospective analysis. *Journal of Clinical Apheresis*, **2019**, 34, 666-671	3.2	4
272	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. *American Journal of Hematology*, **2019**, 94, E231-E234	7.1	4
271	Angiosarcoma of the Prostate Gland following Brachytherapy for Prostatic Adenocarcinoma. *Current Urology*, **2015**, 8, 109-12	1.7	4
270	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). *British Journal of Haematology*, **2020**, 189, e104-e108	4.5	4
269	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. *British Journal of Haematology*, **2020**, 190, e316-e320	4.5	4
268	Subacute demyelinating polyradiculoneuropathy complicating Epstein-Barr virus infection in GATA2 haploinsufficiency. *Muscle and Nerve*, **2018**, 57, 150-156	3.4	4

267	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2016**, 57, 1714-5	1.9	4
266	MYST3/CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer. *Case Reports in Oncological Medicine*, **2014**, 2014, 361748	0.9	4
265	Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.. *American Journal of Hematology*, **2022**,	7.1	4
264	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. *Blood*, **2016**, 128, 4320-4320	2.2	4
263	Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. *Leukemia and Lymphoma*, **2021**, 62, 2568-2586	1.9	4
262	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. *Leukemia Research*, **2016**, 50, 112-115	2.7	4
261	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. *Transplantation and Cellular Therapy*, **2021**, 27, 165.e1-165.e11		4
260	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. *Leukemia and Lymphoma*, **2021**, 62, 764-767	1.9	4
259	Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. *Current Hematologic Malignancy Reports*, **2018**, 13, 341-347	4.4	3
258	QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia. *Leukemia and Lymphoma*, **2019**, 60, 3512-3520	1.9	3
257	GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. *Blood*, **2018**, 132, 961-961	2.2	3
256	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. *Blood*, **2018**, 132, 1773-1773	2.2	3
255	A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2019**, 134, 4234-4234	2.2	3
254	Real-World "myelodysplastic Syndrome-unclassifiable" and Its Comparison With "refractory Cytopenia With Multi-Lineage dysplasia" and "refractory anemia". *Blood*, **2013**, 122, 1574-1574	2.2	3
253	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. *Blood*, **2015**, 126, 55-55	2.2	3
252	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. *Blood*, **2016**, 128, 2798-2798	2.2	3
251	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. *Blood*, **2016**, 128, 3604-3604	2.2	3
250	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. *British Journal of Haematology*, **2021**,	4.5	3

249	Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?. *Seminars in Hematology*, **2021**, 58, 226-229	4	3
248	High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. *American Journal of Hematology*, **2021**, 96, 1647-1654	7.1	3
247	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA venetoclax chemotherapy. *American Journal of Hematology*, **2021**, 96, E108-E111	7.1	3
246	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. *Blood Cancer Journal*, **2021**, 11, 43	7	3
245	Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. *Leukemia*, **2021**, 35, 3299-3303	10.7	3
244	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. *Blood Advances*, **2021**, 5, 2272-2278	7.8	3
243	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. *Leukemia*, **2021**, 35, 2739-2751	10.7	3
242	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. *American Journal of Hematology*, **2019**, 94, 5-9	7.1	3
241	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. *Blood Cancer Journal*, **2021**, 11, 156	7	3
240	The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. *British Journal of Haematology*, **2017**, 178, 57-60	4.5	2
239	FLT3 Mutation Testing in Acute Myeloid Leukemia. *JAMA Oncology*, **2017**, 3, 991-992	13.4	2
238	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. *Leukemia and Lymphoma*, **2019**, 60, 2483-2487	1.9	2
237	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. *American Journal of Hematology*, **2020**, 95, E257	7.1	2
236	Treatment of Acquired Sideroblastic Anemias. *Hematology/Oncology Clinics of North America*, **2020**, 34, 401-420	3.1	2
235	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. *American Journal of Hematology*, **2020**, 95, E86-E89	7.1	2
234	Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. *JAMA Dermatology*, **2020**, 156, 631-639	5.1	2
233	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. *Oncotarget*, **2017**, 8, 94569-94579	3.3	2
232	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. *British Journal of Haematology*, **2018**, 182, 141-145	4.5	2

231	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. *American Journal of Hematology*, **2018**, 93, E355-E357	7.1	2
230	Phenotypic heterogeneity associated with germline haploinsufficiency: a comprehensive kindred study. *Leukemia and Lymphoma*, **2019**, 60, 3282-3286	1.9	2
229	von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges. *British Journal of Haematology*, **2017**, 176, 994-997	4.5	2
228	Influenza infection in neutropenic adults. *Infectious Diseases*, **2017**, 49, 141-146	3.1	2
227	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. *American Journal of Hematology*, **2021**,	7.1	2
226	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. *Blood*, **2019**, 134, 4581-4581	2.2	2
225	Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes. *Blood*, **2019**, 134, 4273-4273	2.2	2
224	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. *Blood*, **2020**, 136, 17-17	2.2	2
223	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. *Blood*, **2013**, 122, 1510-1510	2.2	2
222	Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia. *Blood*, **2015**, 126, 2563-2563	2.2	2
221	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. *Blood*, **2015**, 126, 5234-5234	2.2	2
220	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. *Blood*, **2015**, 126, 736-736	2.2	2
219	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. *Blood*, **2021**, 138, 219-219	2.2	2
218	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). *Blood*, **2021**, 138, 2598-2598	2.2	2
217	Targeting ineffective hematopoiesis in myelodysplastic syndromes. *American Journal of Hematology*, **2021**,	7.1	2
216	Clonal hematopoiesis: Molecular and clinical implications.. *Leukemia Research*, **2022**, 113, 106787	2.7	2
215	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. *Blood*, **2019**, 134, 4248-4248	2.2	2
214	RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis		2

213	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, E68-E72	7.1	2
212	Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
211	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. *American Journal of Clinical Pathology*, **2021**, 156, 679-690	1.9	2
210	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, E327-E330	7.1	2
209	Grey platelet syndrome misdiagnosed as ITP. *British Journal of Haematology*, **2016**, 173, 662	4.5	2
208	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1232-1239	4.7	2
207	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. *Annals of Hematology*, **2019**, 98, 331-337	3	2
206	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. *Leukemia and Lymphoma*, **2019**, 60, 821-824	1.9	2
205	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. *Blood and Lymphatic Cancer: Targets and Therapy*, **2021**, 11, 1-9	2.6	2
204	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162	7.1	2
203	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. *American Journal of Hematology*, **2018**, 93, E401-E404	7.1	2
202	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. *American Journal of Hematology*, **2018**, 93, E383-E386	7.1	2
201	Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms. *American Journal of Hematology*, **2021**, 96, E392-E396	7.1	2
200	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. *American Journal of Hematology*, **2021**, 96, E433-E436	7.1	2
199	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. *British Journal of Haematology*,	4.5	2
198	Characteristics of patients with myelodysplastic syndrome with balanced translocations. *British Journal of Haematology*, **2020**, 190, 244-248	4.5	1
197	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. *Bone Marrow Transplantation*, **2020**, 55, 1879-1881	4.4	1
196	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. *American Journal of Hematology*, **2020**, 95, 1170	7.1	1

195	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. *Annals of Hematology*, **2020**, 99, 513-518	3	1
194	47-Year-Old Man With Pruritus. *Mayo Clinic Proceedings*, **2016**, 91, 241-5	6.4	1
193	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. *Clinical Genitourinary Cancer*, **2018**, 16, e1117-e1122	3.3	1
192	Blast-phase chronic myelomonocytic leukemia: more than just semantics. *Leukemia*, **2018**, 32, 2093-2094	10.7	1
191	Myeloid malignancy presenting with a platelet storage pool disorder. *Leukemia and Lymphoma*, **2013**, 54, 1800-1	1.9	1
190	Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. *Journal of Cutaneous Pathology*, **2017**, 44, 1087-1091	1.7	1
189	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. *American Journal of Hematology*, **2017**, 92, E626-E627	7.1	1
188	ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility. *Blood*, **2020**, 136, 27-28	2.2	1
187	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. *Blood Cancer Journal*, **2022**, 12, 7	7	1
186	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. *Blood Cancer Journal*, **2022**, 12, 26	7	1
185	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. *Haematologica*, **2022**,	6.6	1
184	Erythrocytosis associated with (), (), or mutations: The Mayo Clinic experience.. *Haematologica*, **2022**,	6.6	1
183	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Blood*, **2018**, 132, 3035-3035	2.2	1
182	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. *Blood*, **2019**, 134, 4560-4560	2.2	1
181	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. *Blood*, **2019**, 134, 3003-3003	2.2	1
180	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2020**, 136, 7-8	2.2	1
179	Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. *Blood*, **2013**, 122, 1732-1732	2.2	1
178	Genomics Of Familial Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Blood*, **2013**, 122, 2803-2803	2.2	1

177	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. *Blood*, **2013**, 122, 2821-2821	2.2	1
176	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. *Blood*, **2013**, 122, 4049-4049	2.2	1
175	Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. *Blood*, **2015**, 126, 1923-1923	2.2	1
174	Spectrum of Mutations Associated with Hereditary Erythrocytosis. *Blood*, **2015**, 126, 2140-2140	2.2	1
173	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. *Blood*, **2015**, 126, 3210-3210	2.2	1
172	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 4343-4343	2.2	1
171	Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. *Blood*, **2016**, 128, 4694-4694	2.2	1
170	Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. *Blood Advances*, **2021**,	7.8	1
169	Asxl1loss cooperates with oncogenic Nras in mice to reprogram immune microenvironment and drive leukemic transformation. *Blood*, **2021**,	2.2	1
168	Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2018**, 132, 1813-1813	2.2	1
167	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. *Blood*, **2018**, 132, 5440-5440	2.2	1
166	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). *Blood*, **2019**, 134, 4182-4182	2.2	1
165	Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a. *Blood*, **2019**, 134, 4220-4220	2.2	1
164	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 1476-1476	2.2	1
163	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. *Blood*, **2013**, 122, 3873-3873	2.2	1
162	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. *American Journal of Hematology*, **2020**, 95, E31-E34	7.1	1
161	Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. *Current Opinion in Hematology*, **2020**, 27, 2-10	3.3	1
160	Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. *Blood Cancer Journal*, **2020**, 10, 120	7	1

159	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. *Blood Cancer Journal*, **2021**, 11, 46	7	1
158	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. *Blood Cancer Journal*, **2021**, 11, 54	7	1
157	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. *Leukemia*, **2021**, 35, 3329-3333	10.7	1
156	Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. *Chest*, **2021**, 159, 2325-2333	5.3	1
155	Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. *British Journal of Haematology*, **2021**, 195, 133-137	4.5	1
154	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. *Blood*, **2021**, 137, 513-523	2.2	1
153	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. *Bone Marrow Transplantation*, **2021**, 56, 960-962	4.4	1
152	CDK2-Mediated Upregulation of TNF as a Mechanism of Selective Cytotoxicity in Acute Leukemia. *Cancer Research*, **2021**, 81, 2666-2678	10.1	1
151	In Reply-Short Telomere Syndromes, Biological Aging, and Hematopoietic Stem Cell Transplantation. *Mayo Clinic Proceedings*, **2018**, 93, 1685-1687	6.4	1
150	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E398-E401	7.1	1
149	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. *British Journal of Haematology*, **2021**, 195, 413-416	4.5	1
148	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, 1450-1460	7.1	1
147	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. *American Journal of Hematology*, **2022**,	7.1	1
146	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".. *Blood Cancer Journal*, **2022**, 12, 55	7	1
145	Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders.. *Current Hematologic Malignancy Reports*, **2022**, 17, 61-68	4.4	1
144	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. *Anticancer Research*, **2020**, 40, 3883-3888	2.3	0
143	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. *Blood*, **2011**, 118, 460-460	2.2	0
142	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. *Blood*, **2021**, 138, 3657-3657	2.2	0

141	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. *Blood*, **2021**, 138, 3368-3368	2.2	0
140	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. *Blood*, **2021**, 138, 2158-2158	2.2	0
139	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. *American Journal of Hematology*, **2021**, 97, E62	7.1	0
138	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. *Blood*, **2021**, 138, 3691-3691	2.2	0
137	DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. *Blood*, **2021**, 138, 3693-3693	2.2	0
136	Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. *Blood Cancer Journal*, **2021**, 11, 170	7	0
135	Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression. *Blood*, **2019**, 134, 3790-3790	2.2	0
134	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. *Blood*, **2016**, 128, 1987-1987	2.2	0
133	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. *Blood*, **2016**, 128, 5534-5534	2.2	0
132	No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer. *Blood*, **2011**, 118, 4259-4259	2.2	0
131	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2021**, 41, 328-350	7.1	0
130	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. *Blood Cancer Journal*, **2021**, 11, 63	7	0
129	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. *Blood Cancer Journal*, **2021**, 11, 122	7	0
128	Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin. *Clinical and Experimental Dermatology*, **2019**, 44, e81-e88	1.8	0
127	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. *Leukemia and Lymphoma*, **2021**, 1-6	1.9	0
126	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. *Leukemia Research*, **2022**, 106818	2.7	0
125	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. *American Journal of Hematology*, **2022**,	7.1	0
124	Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a presentation of two cases with dermatologic findings.. *International Journal of Dermatology*, **2022**,	1.7	0

123	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.. *Nature Communications*, **2022**, 13, 1434	17.4	0
122	Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation.. *Leukemia and Lymphoma*, **2022**, 1-9	1.9	0
121	Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 2019-2020	4.7	
120	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. *Case Reports in Hematology*, **2017**, 2017, 6803804	0.7	
119	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E144-E146	7.1	
118	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. *American Journal of Hematology*, **2018**, 93, E103-E107	7.1	
117	Fanconi Anemia-Protean Manifestations of Defective DNA Repair. *Mayo Clinic Proceedings*, **2016**, 91, 824-5	6.4	
116	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. *International Journal of Hematology*, **2016**, 103, 409-15	2.3	
115	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. *Journal of Womenks Health*, **2017**, 26, 1350-1355	3	
114	Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. *Blood*, **2020**, 136, 31-32	2.2	
113	Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model. *Blood*, **2020**, 136, 10-11	2.2	
112	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. *Blood*, **2020**, 136, 26-27	2.2	
111	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. *Blood*, **2020**, 136, 44-44	2.2	
110	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. *Blood*, **2020**, 136, 17-18	2.2	
109	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. *Blood*, **2020**, 136, 34-35	2.2	
108	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. *Blood*, **2020**, 136, 43-44	2.2	
107	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. *Blood*, **2020**, 136, 35-36	2.2	
106	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. *Blood*, **2020**, 136, 30-31	2.2	

105	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. *Blood*, **2020**, 136, 19-20	2.2
104	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.. *Blood Cancer Journal*, **2022**, 12, 12	7
103	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. *Cancer Genetics*, **2021**, 260-261, 1-5	2.3
102	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. *Blood*, **2021**, 138, 1492-1492	2.2
101	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNENIS). *Blood*, **2021**, 138, 1333-1333	2.2
100	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. *Blood*, **2021**, 138, 36-36	2.2
99	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. *Blood*, **2021**, 138, 1267-1267	2.2
98	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 2592-2592	2.2
97	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2021**, 138, 3684-3684	2.2
96	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2021**, 138, 1470-1470	2.2
95	A novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. *Blood Cancer Journal*, **2021**, 11, 183	7
94	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). *Blood*, **2021**, 138, 1096-1096	2.2
93	Histopathologic Characterization of Vexas Syndrome. *Blood*, **2021**, 138, 4656-4656	2.2
92	Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project. *Blood*, **2021** , 138, 2164-2164	2.2
91	3q21 deletion affects GATA2 and is associated with myelodysplastic syndrome. *British Journal of Haematology*, **2021**,	4.5
90	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. *Blood*, **2018**, 132, 1443-1443	2.2
89	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. *Blood*, **2018**, 132, 5510-5510	2.2
88	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. *Blood*, **2018**, 132, 2113-2113	2.2

87	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. *Blood*, **2018**, 132, 3456-3456	2.2
86	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. *Blood*, **2018**, 132, 5241-5241	2.2
85	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268	2.2
84	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. *Blood*, **2018**, 132, 4287-4287	2.2
83	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. *Blood*, **2018**, 132, 582-582	2.2
82	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. *Blood*, **2018**, 132, 4344-4344	2.2
81	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. *Blood*, **2018**, 132, 3050-3050	2.2
80	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. *Blood*, **2018**, 132, 3100-3100	2.2
79	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. *Blood*, **2018**, 132, 2689-2689	2.2
78	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. *Blood*, **2018**, 132, 1771-1771	2.2
77	Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia. *Blood*, **2019**, 134, 4232-4232	2.2
76	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. *Blood*, **2019**, 134, 3005-3005	2.2
75	Epigenomic Determinants of Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. *Blood*, **2019**, 134, 2987-2987	2.2
74	Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes. *Blood*, **2019**, 134, 1222-1222	2.2
73	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). *Blood*, **2019**, 134, 5441-5441	2.2
72	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2019**, 134, 4500-4500	2.2
71	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. *Blood*, **2019**, 134, 5406-5406	2.2
70	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. *Blood*, **2019**, 134, 2981-2981	2.2

69	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. *Blood*, **2019**, 134, 1697-1697	2.2
68	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. *Blood*, **2019**, 134, 3863-3863	2.2
67	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. *Blood*, **2019**, 134, 3300-3300	2.2
66	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. *Blood*, **2019**, 134, 2588-2588	2.2
65	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. *Blood*, **2019**, 134, 1710-1710	2.2
64	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. *Blood*, **2015**, 126, 3730-3730	2.2
63	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). *Blood*, **2015**, 126, 4067-4067	2.2
62	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. *Blood*, **2015**, 126, 5260-5260	2.2
61	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. *Blood*, **2015**, 126, 4980-4980	2.2
60	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. *Blood*, **2015**, 126, 2490-2490	2.2
59	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. *Blood*, **2015**, 126, 4910-4910	2.2
58	Iron Deficiency Anemia Associated with Extracorporeal Photophoresis: A Retrospective Analysis. *Blood*, **2015**, 126, 951-951	2.2
57	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. *Blood*, **2015**, 126, 2875-2875	2.2
56	Clinico-Pathological Features and Outcomes in Patients with Congenital Sideroblastic Anemias. *Blood*, **2015**, 126, 3355-3355	2.2
55	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2015**, 126, 2864-2864	2.2
54	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. *Blood*, **2015**, 126, 1913-1913	2.2
53	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. *Blood*, **2015**, 126, 3747-3747	2.2
52	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. *Blood*, **2015**, 126, 4993-4993	2.2

51	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. *Blood*, **2015**, 126, 5254-5254	2.2
50	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. *Blood*, **2015**, 126, 4370-4370	2.2
49	Incidence and Outcomes of Neutropenia in Patients with Celiac Disease- a Consecutive Analysis of 1729 Patients. *Blood*, **2015**, 126, 1013-1013	2.2
48	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. *Blood*, **2015**, 126, 2882-2882	2.2
47	Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. *Blood*, **2016**, 128, 1617-1617	2.2
46	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. *Blood*, **2016**, 128, 5541-5541	2.2
45	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. *Blood*, **2016**, 128, 300-300	2.2
44	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. *Blood*, **2016**, 128, 4259-4259	2.2
43	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. *Blood*, **2016**, 128, 4653-4653	2.2
42	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 110-110	2.2
41	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. *Blood*, **2016**, 128, 1986-1986	2.2
40	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1988-1988	2.2
39	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2016**, 128, 4593-4593	2.2
38	Coagulation Abnormalities and Hemostatic Surgical Outcomes in 142 Patients with Noonan Syndrome. *Blood*, **2016**, 128, 1417-1417	2.2
37	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. *Blood* , **2016**, 128, 5542-5542	2.2
36	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1989-1989	2.2
35	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making: A Qualitative Patient-Oriented Survey Study. *Blood*, **2016**, 128, 3588-3588	2.2
34	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies. *Blood*, **2016**, 128, 3599-3599	2.2

33	Clinical & Molecular Analysis of Patients with Type 2 (Qualitative) Hereditary Antithrombin (AT) Deficiency. *Blood*, **2010**, 116, 4201-4201	2.2
32	Clinicopathological and Cytogenetic Comparison of Patients with Acute T Lymphoblastic Leukemia and Lymphoblastic Lymphoma. *Blood*, **2010**, 116, 2705-2705	2.2
31	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. *Blood*, **2011**, 118, 3803-3803	2.2
30	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. *Blood*, **2011**, 118, 971-971	2.2
29	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. *Blood*, **2012**, 120, 1711-1711	2.2
28	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). *Blood*, **2012**, 120, 600-600	2.2
27	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥1% Ring Sideroblasts.. *Blood*, **2012**, 120, 2803-2803	2.2
26	Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.. *Blood*, **2012**, 120, 2850-2850	2.2
25	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. *Blood*, **2012**, 120, 3790-3790	2.2
24	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). *Blood*, **2012**, 120, 423-423	2.2
23	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. *Blood*, **2013**, 122, 1405-1405	2.2
22	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. *Blood*, **2013**, 122, 2794-2794	2.2
21	Clinical and Molecular Profile Of Hereditary Antithrombin (AT) Deficiency: A Single Institution Cohort. *Blood*, **2013**, 122, 2369-2369	2.2
20	Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis. *Blood*, **2013**, 122, 5472-5472	2.2
19	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. *Blood*, **2013**, 122, 4048-4048	2.2
18	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. *Blood*, **2013**, 122, 4955-4955	2.2
17	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. *Blood*, **2013**, 122, 2098-2098	2.2
16	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. *Blood*, **2013**, 122, 5226-5226	2.2

15	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1334-1334	2.2
14	Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients. *Blood*, **2013**, 122, 916-916	2.2
13	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. *Blood*, **2013**, 122, 3375-3375	2.2
12	Incidence Of Symptomatic Venous Thromboembolism In Patients With Hemophilia Undergoing Joint Replacement Surgery: A Retrospective Study. *Blood*, **2013**, 122, 2348-2348	2.2
11	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. *Blood*, **2013**, 122, 2081-2081	2.2
10	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. *Blood*, **2013**, 122, 5000-5000	2.2
9	Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment. *Best Practice and Research in Clinical Haematology*, **2020**, 33, 101130	4.2
8	Novel therapeutic targets for chronic myelomonocytic leukemia. *Best Practice and Research in Clinical Haematology*, **2021**, 34, 101244	4.2
7	Treatment advances for pediatric and adult onset neoplasms with monocytosis. *Current Hematologic Malignancy Reports*, **2021**, 16, 256-266	4.4
6	Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. *Kidney International Reports*, **2021**, 6, 1050-1057	4.1
5	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. *Leukemia Research*, **2019**, 87, 106264	2.7
4	Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. *Bone Marrow Transplantation*, **2021**, 56, 508-510	4.4
3	45-Year-Old Man With Abdominal Pain and Splenomegaly. *Mayo Clinic Proceedings*, **2018**, 93, e113-e117	6.4
2	Isolated T-cell acute lymphoblastic leukemic optic disc infiltration. *American Journal of Hematology*, **2021**, 96, 1717-1718	7.1
1	A Man with Progressive Effort Intolerance and Splenomegaly393-399	